ArticleCell reports2023
Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.
Article in Cell reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 187 citations in OpenAlex.
- Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.Human vaccines & immunotherapeutics · 2024Trial
- Trivalent recombinant protein vaccine induces cross-neutralization against XBB lineage and JN.1 subvariants: preclinical and phase 1 clinical trials.Nature communications · 2024Trial
- Disulfide bonds stabilize the SARS-CoV-2 RBD and preserve binding to ACE2 following thermal denaturation.Bioscience reports · 2026Article
- First Responders Have Lower COVID-19 Vaccination Rates Than Other Healthcare Providers.Journal of the American College of Emergency Physicians open · 2026Article
- Somatic Evolution of a Germline Antibody Expands its Breadth to Neutralize Early SARS-CoV-2 Omicron Variants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A Multiepitope Intranasal Adenoviral Vaccine Induces Robust Mucosal Immunity and Protection against SARS‑CoV‑2.Journal of nanobiotechnology · 2026Article
- Review
- Combination of adenovirus vector and subunit protein elicits a robust immune response against the SARS-CoV-2 Omicron variant.Molecular biomedicine · 2026Article
- Article
- Longitudinal analysis of neutralizing antibodies against SARS-CoV-1 and different SARS-CoV-2 strains in breakthrough and unvaccinated COVID-19 patients in Thailand (2021-2022).Scientific reports · 2026Article
- Impacts of neutralizing antibody responses on SARS-CoV-2 evolution and its associated disease progression.Immunity & inflammation · 2026Article
- COVID19 Sero-epidemiology and vaccine uptake in two Southern Nigerian clinics.PLOS global public health · 2026Article
- Age-dependent immune profiles and variant-driven humoral alterations across two SARS-CoV-2 epidemic phases.Frontiers in immunology · 2026Article
- Increased pathogenicity and transmission of SARS-CoV-2 Omicron XBB.1.9 subvariants, including HK.3 and EG.5.1, relative to BA.2.Journal of virology · 2025Article
- Virological characterization of SARS-CoV-2 BA.2.86 variants by assessing antiviral susceptibility, in vivo infectivity and replicative fitness.Scientific reports · 2025Article
- Cross-neutralization of human sera with diverse SARS-CoV-2 omicron exposure histories, 2022-2024: Evidence of immune heterogeneity.One health (Amsterdam, Netherlands) · 2025Article
- Enhanced variant neutralization through glycan masking of SARS-CoV-2 XBB1.5 RBD.Emerging microbes & infections · 2025Article
- Article
- Comparing neutralizing antibody activity over time between naïve and convalesced COVID-19 vaccinated individuals.Scientific reports · 2025Article
- Evaluation of SARS-CoV-2 Variants After the Declaration of End of COVID-19 Pandemic: BA.2.86 (Pirola) and EG.5 (Eris) Variants as Global Public Health Concerns.Health science reports · 2025Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
17 authors at 3 institutions in 1 country.
Funding
Abstract
Omicron subvariants continuingly challenge current vaccination strategies. Here, we demonstrate nearly complete escape of the XBB.1.5, CH.1.1, and CA.3.1 variants from neutralizing antibodies stimulated by three doses of mRNA vaccine or by BA.4/5 wave infection, but neutralization is rescued by a BA.5-containing bivalent booster. CH.1.1 and CA.3.1 show strong immune escape from monoclonal antibody S309. Additionally, XBB.1.5, CH.1.1, and CA.3.1 spike proteins exhibit increased fusogenicity and enhanced processing compared with BA.2. Homology modeling reveals the key roles of G252V and F486P in the neutralization resistance of XBB.1.5, with F486P also enhancing receptor binding. Further, K444T/M and L452R in CH.1.1 and CA.3.1 likely drive escape from class II neutralizing antibodies, whereas R346T and G339H mutations could confer the strong neutralization resistance of these two subvariants to S309-like antibodies. Overall, our results support the need for administration of the bivalent mRNA vaccine and continued surveillance of Omicron subvariants.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.